TrimixDC-NEO

Project Details

Description

This grant will help us to develop an investigator initiated clinical trial using our
dendritic cell technology. We will develop a personalized immunotherapy
targeting neoantigens. We will test the feasibility, safety and tolerability of
such a therapy. The biological activity will be measured by analyses of the
immune responses and by documenting changes in immune infiltration within
the tumor (immunohistochemistry), changes in immune-related gene
expression profile (Nanostring) and changes in the TCR repertoire (TCR-b
chain sequencing).

Initially the target neoantigens will be selected using our computational
pipeline. However, in parallel and using the whole exome and transcriptome
data from the patients enrolled for this investigator initiated trial, we will further
improve the selection of the target antigens by combining the computational
prioritization and a mass spectrometry-based approach (grant application
submitted). Once the selection of neoantigen candidates recognizable by T
cells has been improved, this will also implemented in this trial.
Short title or EU acronymTrimixDC-NEO
AcronymANI215
StatusActive
Effective start/end date1/01/1931/12/22

Keywords

  • Investigator
  • clinical trial
  • dendritic cell technology
  • Immunotherapy

Flemish discipline codes

  • Hematology
  • Cancer therapy
  • Cancer diagnosis